Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Animal tissue

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Animal tissue. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-002646-35 Sponsor Protocol Number: 8514077463 Start Date*: 2005-10-18
    Sponsor Name:Franz Volhard Clinic, Charite Campus Buch
    Full Title: Pilot study for evaluation of growth factor erythropoietin beta for improvement of left ventricular function after coronary interventions
    Medical condition: Ischemic heart failure is a major public health burden in western societies. Although technical advancements have improved recascularization of ischemic heart tissue in recent years, data on funct...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005026-21 Sponsor Protocol Number: 1403740 Start Date*: 2012-01-31
    Sponsor Name:KYTHERA Biopharmaceuticals, Inc.
    Full Title: Long-term, follow-up study of subjects who completed phase III trials ATX-101-10-16 or ATX-101-10-17 (sodium deoxycholate injection) for the reduction of localized subcutaneous fat in the submental...
    Medical condition: Reduction of subcutaneous fat in the submental area
    Disease: Version SOC Term Classification Code Term Level
    17.1 10018065 - General disorders and administration site conditions 10016251 Fat tissue increased PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019991-55 Sponsor Protocol Number: CC-10004-PSOR-008 Start Date*: 2011-01-25
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis
    Medical condition: Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's population. Plaque-type psoriasis is the most common form of this disease.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019992-30 Sponsor Protocol Number: CC-10004-PSOR-009 Start Date*: 2010-12-16
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis
    Medical condition: Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's population. Plaque-type psoriasis is the most common form of this disease.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001206-24 Sponsor Protocol Number: 16901 Start Date*: 2007-07-31
    Sponsor Name:UMCG
    Full Title: Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001599-18 Sponsor Protocol Number: BAY 12-8039/11974 Start Date*: 2006-11-03
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, randomized, double dummy, double blind, multinational, multicenter trial comparing the safety and efficacy of sequential (intravenous/oral) moxifloxacin 400 mg once daily to intraven...
    Medical condition: complicated skin and skin structure Infections
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040786 Skin structures and soft tissue infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) BE (Completed) LV (Completed) FR (Completed) GR (Completed) IE (Completed) HU (Completed) ES (Completed) NL (Prematurely Ended) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004393-28 Sponsor Protocol Number: 06-2011 Start Date*: 2012-07-12
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: "Effectiveness of leech therapy in treatment of chronic low back pain - a randomised controlled clinical study"
    Medical condition: chronic low back pain -diagnosis assured by specialist (orthopedy, neurology, pain therapy) as chronic low back pain for at least 3 month caused by nonspecific lumbar syndrome - averaged pain int...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002692-34 Sponsor Protocol Number: MitoFibrateCT1-2012 Start Date*: 2013-06-26
    Sponsor Name:Univ.-Klinik für Kinder- und Jugendheilkunde
    Full Title: Clinical study for the assessment of safety and efficacy of Bezafibrate as a drug therapy for patients with mitochondrial myopathies
    Medical condition: mitochondrial disorder
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019926-15 Sponsor Protocol Number: CC-10004-RA-002 Start Date*: 2011-01-27
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO COMPARE THE EFFICACY AND SAFETY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE RHEUMATO...
    Medical condition: Rheumatoid arthritis, a chronic systemic autoimmune inflammatory disease characterized by persisten synovial inflammations.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001284-44 Sponsor Protocol Number: MEDLARV-CLIN-01 Start Date*: 2011-11-14
    Sponsor Name:MAGGOT 2006 Egészségügyi, Kereskedelmi és Szolgáltató Ltd.
    Full Title: A RANDOMIZED, OPEN, SELF-CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF LARVAL THERAPY IN PATIENTS WITH LEG ULCERS
    Medical condition: Venous or mixed venous/arterial ulcers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020324-22 Sponsor Protocol Number: CC-10004-PSA-005 Start Date*: 2011-03-07
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who...
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6 to 39% of patients with psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) CZ (Completed) LT (Completed) IT (Completed) PL (Completed) BG (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000901-19 Sponsor Protocol Number: PSA‐PI‐006421 Start Date*: 2017-09-11
    Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
    Full Title: Evaluation of the clinical and echographic response to Apremilast through clinical evaluation and through a joint-periarticular-nail echographic index in patients with active psoriatic arthritis.
    Medical condition: Psoriasic arthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-000859-14 Sponsor Protocol Number: CC-10004-PSOR-010 Start Date*: 2013-01-17
    Sponsor Name:Celgene Corporation
    Full Title: A phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, In Subjects with Moderate to...
    Medical condition: Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's population. Plaque-type psoriasis is the most common form of this disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) NL (Completed) CZ (Completed) LV (Completed) EE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-000319-18 Sponsor Protocol Number: FW-UC-001 Start Date*: 2018-02-07
    Sponsor Name:FIRST WAVE BIOPHARMA INCORPORATION
    Full Title: A phase I/IIa, open-label, three-stage, study to investigate the safety, the efficacy and the pharmacokinetics of Niclosamide enemas in subjects with active Ulcerative Proctitis or Ulcerative Proct...
    Medical condition: Active ulcerative proctitis or ulcerative procto-sigmoiditis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10036783 Proctitis ulcerative PT
    20.0 10017947 - Gastrointestinal disorders 10036789 Proctosigmoiditis LLT
    20.1 10017947 - Gastrointestinal disorders 10045362 Ulcerative (chronic) proctosigmoiditis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Prematurely Ended) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019941-24 Sponsor Protocol Number: CC-10004-PSA-004 Start Date*: 2010-12-01
    Sponsor Name:Celgene Corporation
    Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis and...
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that, depending on the method of ascertainment, occurs in 6 to 39% of patients with psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) FI (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004738-27 Sponsor Protocol Number: A011-09 Start Date*: 2018-08-15
    Sponsor Name:Acceleron Pharma Inc.
    Full Title: A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonar...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077739 Pulmonary arterial hypertension WHO functional class I LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000199-12 Sponsor Protocol Number: A011-13 Start Date*: 2022-07-19
    Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and Hig...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) SE (Prematurely Ended) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2005-001771-35 Sponsor Protocol Number: FFR104503 Start Date*: 2005-10-04
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Centre, 52-Week Study to Assess the Long Term Safety of GW685698X Aque...
    Medical condition: Perennial Allergic Rhinitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002981-64 Sponsor Protocol Number: CC-10004-UC-001 Start Date*: 2015-08-13
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS
    Medical condition: Subjects with active ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003284-62 Sponsor Protocol Number: 012508 Start Date*: 2019-07-18
    Sponsor Name:Queen Mary University London
    Full Title: A randomised, blinded, placebo controlled, Phase 2a study to evaluate the safety and efficacy of administering Regadenoson to patients with critical injury and signs of haemorrhagic shock
    Medical condition: Cardiovascular collapse following traumatic haemorrhage
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 12 20:55:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA